Vanda Pharmaceuticals price to sales ratio VNDA

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 1.1×
10-year median: 2.5×
Against its 10-year history: 4th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.9× to 8.8×
Peer median: 1.4×

Vanda Pharmaceuticals' price to sales ratio is 1.1× as of Oct 23, 2026.

That is below its ten-year median of 2.5×, lower than on 96% of days in the last ten years.

Over that time it ranged from 0.9× in Nov 2023 to 8.8× in Jan 2019.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

median 2.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.1×	1.1×	2.4×
2025	2.0×	1.2×	2.0×
2024	1.5×	1.0×	2.0×
2023	1.1×	0.9×	1.7×
2022	1.6×	1.5×	3.2×
2021	3.3×	3.1×	4.6×
2020	3.0×	2.0×	3.9×
2019	4.1×	3.2×	8.8×
2018	7.3×	3.9×	7.9×
2017	4.3×	3.6×	5.3×
2016	5.0×	3.0×	5.6×
2015	4.3×	3.9×	11.3×
2014	11.7×	8.1×	18.5×
2013	12.3×	3.2×	14.7×
2012	3.0×	2.6×	4.0×

Against its peers

Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
VNDAVanda Pharmaceuticals	1.1×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
LFVNLifevantage	0.4×
ABUSArbutus Biopharma	4.6×
SPROSpero Therapeutics	1.4×
Peer median	1.4×

Where Vanda Pharmaceuticals ranks

#24of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Vanda Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.